Human anti-IP-10 antibodies uses thereof
The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-IO, CXCL1O), thereby modulating the interaction between IP-IO and its receptor, CXCR3, and/or modulating the biological activities of IP-IO. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
1. An isolated fully human monoclonal anti-IP-10 antibody or fragment thereof, wherein said antibody comprises:
(a) a V H CDR1 region comprising the amino acid sequence of SEQ ID NO: 5;
(b) a V H CDR2 region comprising the amino acid sequence of SEQ ID NO: 15; and
(c) a V H CDR3 region comprising the amino acid sequence of SEQ ID NO: 21;
(d) a V L CDR1 region comprising the amino acid sequence of SEQ ID NO: 16;
(e) a V L CDR2 region comprising the amino acid sequence of SEQ ID NO: 9; and
(f) a V L CDR3 region comprising the amino acid sequence of SEQ ID NO: 29, wherein said antibody binds IP-10.
2. The antibody of claim 1 , wherein said antibody is an IgG isotype.
3. The antibody of claim 1 , wherein said antibody is an IgG1 isotype.
4. An isolated fully human monoclonal antibody, wherein said antibody comprises the heavy chain variable amino acid sequence of SEQ ID NO: 18, wherein said antibody further comprises the light chain variable amino acid sequence of SEQ ID NO: 28, and wherein said antibody binds IP-10.
5. The antibody of claim 4 , wherein said antibody is an IgG isotype.
6. The antibody of claim 4 , wherein said antibody is an IgG1 isotype.
7. A pharmaceutical composition comprising the antibody of claim 1 and a carrier.